Nine Diagnostics was invited to present at the FNIH Biomarkers Consortium 20th Anniversary Symposium, held February 9-10, 2026, at the Bethesda North Marriott Hotel and Conference Center in North Bethesda, Maryland. The event brought together scientists, regulators, industry leaders, and patient advocates from across the public-private partnership ecosystem to reflect on two decades of progress in biomarker science and chart future directions for clinical and regulatory application.
The FNIH Biomarkers Consortium is one of the most consequential cross-sector collaborations in biomedical research. Since its founding, the Consortium has united leaders from the NIH, FDA, CMS, academia, and more than 70 life sciences companies and nonprofit organizations. Over 20 years it has validated 35 scientifically qualified biomarker methods and materials, contributed to 26 advanced therapeutics, supported 10 FDA guidance documents, and generated more than 200 publications. It operates at the intersection of regulatory science, clinical development, and translational medicine, with an emphasis on moving biomarker discoveries from the bench through regulatory qualification and into routine clinical use.
The symposium’s keynote addresses reflected the breadth of this mission. Dr. Janet Woodcock, former Principal Deputy Commissioner of the FDA, discussed the evolution and promise of biomarkers in transforming drug development and clinical decision-making. Dr. Eliav Barr, SVP, Head of Global Clinical Development and Chief Medical Officer at Merck, offered the perspective of a leading drug developer on how validated biomarkers are reshaping clinical trial design and therapeutic selection.
A recurring theme across sessions was the shift from individual biomarkers toward integrated, multi-signal approaches. Speakers emphasized the growing role of AI-driven analytics in making sense of complex biological datasets and the importance of cross-sector collaboration in generating the scale of evidence needed to support regulatory qualification.
Nine Diagnostics’ AI-enabled multi-omic nanosensor platform sits directly at this intersection. The platform generates molecular fingerprints that combine proteomic, metabolomic, and lipidomic information alongside patient clinical context, and applies machine learning to identify disease-relevant patterns without requiring prior knowledge of which biomarkers matter. This positions Nine Diagnostics within a broader field-wide movement toward biomarker-agnostic, data-driven diagnostics that can support patient stratification, treatment selection, and response monitoring.
Presentation at the FNIH Biomarkers Consortium Symposium reflects Nine Diagnostics’ growing engagement with the biomarker validation and regulatory ecosystem, and its commitment to advancing the platform within the scientific and policy frameworks that will govern the next generation of clinical biomarker tools. For an early-stage company developing a novel measurement paradigm, access to the FNIH network of regulators, payers, and industry leaders is directly relevant to the qualification pathway that underpins clinical and commercial adoption.
Read the FNIH announcement marking 20 years of the Biomarkers Consortium.
About Nine Diagnostics
Nine Diagnostics is an AI-enabled multi-omic nanosensor company advancing precision medicine. The platform simultaneously captures proteomic, metabolomic, and lipidomic signals alongside patient clinical context to generate a multi-omic fingerprint, using machine learning to identify disease-relevant patterns without requiring prior knowledge of which biomarkers matter. This enables pre-treatment patient stratification, on-treatment response monitoring, and post-treatment minimal residual disease detection. Founded by Freddy T. Nguyen, MD, PhD (CEO), Daniel A. Heller, PhD (CSO), and Mijin Kim, PhD (Scientific Advisor), Nine Diagnostics is based in Cambridge, Massachusetts.